| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8658198 | OREXO US INC | Non-abusable pharmaceutical composition comprising opioids |
Dec, 2027
(4 years from now) | |
| US8470361 | OREXO US INC | Non-abusable pharmaceutical composition comprising opioids |
May, 2030
(6 years from now) | |
| US11020388 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
| US11020387 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
| US10946010 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
| US8940330 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
| US9439900 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
| US9259421 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
| US10874661 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
| US11433066 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
Zubsolv is owned by Orexo Us Inc.
Zubsolv contains Buprenorphine Hydrochloride; Naloxone Hydrochloride.
Zubsolv has a total of 10 drug patents out of which 0 drug patents have expired.
Zubsolv was authorised for market use on 03 July, 2013.
Zubsolv is available in tablet;sublingual dosage forms.
Zubsolv can be used as use of zubsolv for treatment of opioid dependence, sublingual administration of a pharmaceutical composition comprising buprenorphine and naloxone, sublingual or buccal administration of a pharmaceutical composition comprising buprenorphine and naloxone.
The generics of Zubsolv are possible to be released after 18 September, 2032.
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 July, 2013
Treatment: Sublingual or buccal administration of a pharmaceutical composition comprising buprenorphine and naloxone; Sublingual administration of a pharmaceutical composition comprising buprenorphine and naloxo...
Dosage: TABLET;SUBLINGUAL
ZUBSOLV family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic